Nanoparticles overcome adaptive immune resistance and enhance immunotherapy via targeting tumor microenvironment in lung cancer

Lung cancer is one of the common malignant cancers worldwide. Immune checkpoint inhibitor (ICI) therapy has improved survival of lung cancer patients. However, ICI therapy leads to adaptive immune resistance and displays resistance to PD-1/PD-L1 blockade in lung cancer, leading to less immune respon...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xin, Wang, Xuemei, Hou, Lijian, Xu, Zheng, Liu, Yu’e, Wang, Xueju
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080031/
https://www.ncbi.nlm.nih.gov/pubmed/37033636
http://dx.doi.org/10.3389/fphar.2023.1130937

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10080031/
https://www.ncbi.nlm.nih.gov/pubmed/37033636
http://dx.doi.org/10.3389/fphar.2023.1130937

Ejemplares similares